Debt retirement removes secured-debt overhang and covenant constraints, a clear credit-positive event for a $14M market cap company. However, the cash used for repayment reduces the cash runway — watch the next 10-Q for updated cash position and any going-concern disclosure. The stock may see a modest relief rally on the deleveraging signal.
Price Chart
Executive Summary
Bionano Genomics fully retired its $20M Senior Secured Convertible Debentures using cash on hand, eliminating all secured debt, liens, and restrictive covenants. This strengthens the balance sheet and provides greater financial flexibility, though the cash drain raises questions about runway given the company's going-concern risk noted in forward-looking statements.
Key Facts
- All outstanding Senior Secured Convertible Debentures were repaid in full on May 26, 2026, the scheduled maturity date.
- Debentures were originally issued in May 2024 with an aggregate face value of $20,000,000.
- Repayment was made using cash on hand.
- All liens on company assets and associated restrictive covenants have been terminated.
- Company now carries no outstanding secured debt obligations.
Financial Impact
$20M debt retired using cash on hand; no new financing required.
Risk Factors
- Cash on hand used for repayment may accelerate need for additional financing if operating cash burn continues.
- Forward-looking statements reiterate going-concern risk and need for significant additional capital.
- No new revenue or operational catalyst — this is a balance-sheet cleanup, not a growth event.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001411690-26-000033 |
| Document: bngo-ex99_1.htm | 0001411690-26-000033 |
| Document: 0001411690-26-000033-index-headers.html | 0001411690-26-000033 |
| Document: 0001411690-26-000033-index.html | 0001411690-26-000033 |
| Document: 0001411690-26-000033.txt | 0001411690-26-000033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $1.22 $1.16 | ▼ −4.92% | ▼ −4.77% | $1.17 (−3.69%) |
Sep 14, 2026 6w ago | Press Release | $1.33 $1.83 | ▲ +37.59% | ▲ +37.49% | $1.17 (−11.65%) |
Sep 14, 2026 6w ago | 8-K | $1.33 $1.83 | ▲ +37.59% | ▲ +37.49% | $1.17 (−11.65%) |
Aug 10, 2026 11w ago | 8-K | $1.19 $1.18 | ▼ −0.84% | ▼ −0.44% | $1.17 (−1.26%) |
Jun 5, 2026 20w ago | 8-K | $1.17 $1.16 | ▲ +0.85% | ▲ +2.97% | $1.17 (−0.43%) |
May 28, 2026 21w ago | 8-K | $1.25 $1.30 | ▲ +4.00% | ▲ +4.05% | $1.17 (−6.00%) |
Mar 23, 2026 31w ago | Press Release | $1.18 $1.17 | ▲ +0.85% | ▲ +0.42% | $1.17 (+0.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers